Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sentana-Lledo

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Therapeutic Advances in Medical Oncology|December 19, 2022
Optimal assessment of quality of life for patients with prostate cancerLogan G Briggs, Daniel Sentana-Lledo, Daniel E Lage, et al.
Journal of Virology|March 25, 2016
HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr VirusJayaraju Dheekollu, Andreas Wiedmer, Daniel Sentana-Lledo, et al.
Journal of Medical Entomology|October 18, 2015
Seasons, Searches, and Intentions: What The Internet Can Tell Us About The Bed Bug (Hemiptera: Cimicidae) EpidemicDaniel Sentana-Lledo, Corentin M Barbu, Michelle N Ngo, et al.
Translational Lung Cancer Research|August 14, 2023
<i>EGFR</i> exon 20 insertion mutations and <i>ERBB2</i> mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugatesDaniel Sentana-Lledo, Emmeline Academia, Hollis Viray, et al.
Frontiers in Oncology|October 13, 2025
Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimenDaniel Sentana-Lledo, Arjun Gupta, Carmine Rossi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2023
EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitorsWilliam Shaffer, Ikei S Kobayashi, Daniel Sentana-Lledo, et al.
European Urology Oncology|April 30, 2024
Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)Daniel Sentana-Lledo, Xiangying Chu, David F Jarrard, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2022
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancerDaniel Sentana-Lledo, Hollis Viray, Andrew J Piper-Vallillo, et al.
JCO Oncology Practice|April 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDaniel Sentana-Lledo, Avina Rami, Caiwei Zhong, et al.
European Urology Oncology|April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trialDaniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Therapeutic Advances in Medical Oncology|December 19, 2022
Optimal assessment of quality of life for patients with prostate cancerLogan G Briggs, Daniel Sentana-Lledo, Daniel E Lage, et al.
Journal of Virology|March 25, 2016
HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr VirusJayaraju Dheekollu, Andreas Wiedmer, Daniel Sentana-Lledo, et al.
Journal of Medical Entomology|October 18, 2015
Seasons, Searches, and Intentions: What The Internet Can Tell Us About The Bed Bug (Hemiptera: Cimicidae) EpidemicDaniel Sentana-Lledo, Corentin M Barbu, Michelle N Ngo, et al.
Translational Lung Cancer Research|August 14, 2023
<i>EGFR</i> exon 20 insertion mutations and <i>ERBB2</i> mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugatesDaniel Sentana-Lledo, Emmeline Academia, Hollis Viray, et al.
Frontiers in Oncology|October 13, 2025
Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimenDaniel Sentana-Lledo, Arjun Gupta, Carmine Rossi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2023
EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitorsWilliam Shaffer, Ikei S Kobayashi, Daniel Sentana-Lledo, et al.
European Urology Oncology|April 30, 2024
Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)Daniel Sentana-Lledo, Xiangying Chu, David F Jarrard, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2022
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancerDaniel Sentana-Lledo, Hollis Viray, Andrew J Piper-Vallillo, et al.
JCO Oncology Practice|April 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDaniel Sentana-Lledo, Avina Rami, Caiwei Zhong, et al.
European Urology Oncology|April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trialDaniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Pageof 3